nach oben

Erschienen in:

16.02.2018 | Original Article

Prognostic implications of ⁶²Cu-diacetyl-bis (N⁴-methylthiosemicarbazone) PET/CT in patients with glioma

verfasst von: Akira Toriihara, Makoto Ohtake, Kensuke Tateishi, Ayako Hino-Shishikura, Tomohiro Yoneyama, Yoshio Kitazume, Tomio Inoue, Nobutaka Kawahara, Ukihide Tateishi

Erschienen in: Annals of Nuclear Medicine |

Einloggen, um Zugang zu erhalten

Abstract

Objective

The potential of positron emission tomography/computed tomography using ⁶²Cu-diacetyl-bis (N⁴-methylthiosemicarbazone) (⁶²Cu-ATSM PET/CT), which was originally developed as a hypoxic tracer, to predict therapeutic resistance and prognosis has been reported in various cancers. Our purpose was to investigate prognostic value of ⁶²Cu-ATSM PET/CT in patients with glioma, compared to PET/CT using 2-deoxy-2-[¹⁸F]fluoro-d-glucose (¹⁸F-FDG).

Method

56 patients with glioma of World Health Organization grade 2–4 were enrolled. All participants had undergone both ⁶²Cu-ATSM PET/CT and ¹⁸F-FDG PET/CT within mean 33.5 days prior to treatment. Maximum standardized uptake value and tumor/background ratio were calculated within areas of increased radiotracer uptake. The prognostic significance for progression-free survival and overall survival were assessed by log-rank test and Cox’s proportional hazards model.

Results

Disease progression and death were confirmed in 37 and 27 patients in follow-up periods, respectively. In univariate analysis, there was significant difference of both progression-free survival and overall survival in age, tumor grade, history of chemoradiotherapy, maximum standardized uptake value and tumor/background ratio calculated using ⁶²Cu-ATSM PET/CT. Multivariate analysis revealed that maximum standardized uptake value calculated using ⁶²Cu-ATSM PET/CT was an independent predictor of both progression-free survival and overall survival (p < 0.05). In a subgroup analysis including patients of grade 4 glioma, only the maximum standardized uptake values calculated using ⁶²Cu-ATSM PET/CT showed significant difference of progression-free survival (p < 0.05).

Conclusions

⁶²Cu-ATSM PET/CT is a more promising imaging method to predict prognosis of patients with glioma compared to ¹⁸F-FDG PET/CT.

Nur mit Berechtigung zugänglich

Lopci E, Grassi I, Chiti A, Nanni C, Cicoria G, Toschi L, et al. PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. Am J Nucl Med Mol Imaging. 2014;4:365–384.PubMedPubMedCentral

Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155–60.PubMed

Obata A, Yoshimi E, Waki A, Lewis JS, Oyama N, Welch MJ, et al. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cu-diacetyl-bis (N ⁴-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med. 2001;15:499–504.CrossRefPubMed

Tateishi K, Tateishi U, Sato M, Yamanaka S, Kanno H, Murata H, et al. Application of ⁶²Cu-diacetyl-bis (N ⁴-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1α expression in patients with glioma. AJNR Am J Neuroradiol. 2013;34:92 – 9.CrossRefPubMed

Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with ⁶⁰Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys. 2003;55:1233–8.CrossRefPubMed

Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by PET with ⁶⁰Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med. 2008;49:201–5.CrossRefPubMed

Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, et al. In vivo assessment of tumor hypoxia in lung cancer with ⁶⁰Cu-ATSM. Eur J Nucl Med Mol Imaging 2003;30:844–50.CrossRefPubMed

Kinoshita T, Fujii H, Hayashi Y, Kamiyama I, Ohtsuka T, Asamura H. Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer. Lung Cancer. 2016;91:56–66.CrossRefPubMed

Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, et al. Tumor hypoxia detected by positron emission tomography with ⁶⁰Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum. 2008;51:1641–8.CrossRefPubMedPubMedCentral

10.

Sato Y, Tsujikawa T, Oh M, Mori T, Kiyono Y, Fujieda S, et al. Assessing tumor hypoxia in head and neck cancer by PET with ⁶²Cu-diacetyl-bis(N ⁴-methylthiosemicarbazone). Clin Nucl Med. 2014;39:1027–32.CrossRefPubMed

11.

Tateishi K, Tateishi U, Nakanowatari S, Ohtake M, Minamimoto R, Suenaga J, et al. ⁶²Cu-diacetyl-bis (N ⁴-methylthiosemicarbazone) PET in human gliomas: comparative study with [¹⁸F]fluorodeoxyglucose and l-methyl-[¹¹C]methionine PET. AJNR Am J Neuroradiol. 2014;35:278 – 84.CrossRefPubMed

12.

Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefPubMed

13.

Chiang GC, Galla N, Ferraro R, Kovanlikaya I. The added prognostic value of metabolic tumor size on FDG-PET at first suspected recurrence of glioblastoma multiforme. J Neuroimaging. 2017;27:243–7.CrossRefPubMed

14.

Leiva-Salinas C, Schiff D, Flors L, Patrie JT, Rehm PK. FDG PET/MR imaging coregistration helps predict survival in patients with glioblastoma and radiologic progression after standard of care treatment. Radiology. 2017;283:508 – 14.CrossRefPubMed

15.

Colavolpe C, Metellus P, Mancini J, Barrie M, Bequet-Boucard C, Figarella-Branger D, et al. Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas. J Neurooncol. 2012;107:527 – 35.CrossRefPubMed

16.

Tralins KS, Douglas JG, Stelzer KJ, Mankoff DA, Silbergeld DL, Rostomilly R, et al. Volumetric analysis of ¹⁸F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med. 2002;42:1667–73.

17.

Toyonaga T, Yamaguchi S, Hirata K, Kobayashi K, Manabe O, Watanabe S, et al. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor. Eur J Nucl Med Mol Imaging. 2017;44:611–9.CrossRefPubMed

18.

Kawai N, Lin W, Cao WD, Ogawa D, Miyake K, Haba R, et al. Correlation between ¹⁸F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas. Eur J Nucl Med Mol Imaging. 2014;41:1870–8.CrossRefPubMed

19.

Swanson KR, Chakraborty G, Wang CH, Rockne R, Harpold HLP, Muzi M, et al. Complementary but distinct roles for MRI and ¹⁸F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med. 2009;50:36–44.CrossRefPubMed

20.

Spence AM, Muzi M, Swanson KR, O’Sullivan F, Rockhill JK, Rajendran JG, et al. Regional hypoxia in glioblastoma multiforme quantified with [¹⁸F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res. 2008;14:2623–30.CrossRefPubMedPubMedCentral

21.

Carlin S, Zhang H, Reese M, Ramos NN, Chen Q, Ricketts SA. A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers. J Nucl Med. 2014;55:515 – 21.CrossRefPubMedPubMedCentral

22.

O’Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N ⁴-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys. 2005;61:1493–502.CrossRefPubMed

23.

Furukawa T, Yuan Q, Jin ZH, Aung W, Yoshii Y, Hasegawa S, et al. A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-d-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone]. Oncol Rep. 2015;34:1379–87.CrossRefPubMed

24.

Troost EG, Laverman P, Kaanders JH, Philippens M, Lok J, Oyen WJ, et al. Imaging hypoxia after oxygenation-modification: comparing [¹⁸F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. Radiother Oncol. 2006;80:157 – 64.CrossRefPubMed

25.

Busk M, Mortensen LS, Nordsmark M, Overgaard J, Jakobsen S, Hansen KV, et al. PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice. Eur J Nucl Med Mol Imaging. 2013;40:186 – 97.CrossRefPubMed

26.

Li F, Jorgensen JT, Forman J, Hansen AE, Kjaer A. ⁶⁴Cu-ATSM reflects pO₂ levels in human head and neck cancer xenografts but not in colorectal cancer xenografts: comparison with ⁶⁴CuCl₂. J Nucl Med. 2016;57:437 – 43.CrossRefPubMed

27.

Colombie M, Gouard S, Frindel M, Vidal A, Cherel M, Kraeber-Bodere F, et al. Focus on the controversial aspects of ⁶⁴Cu-ATSM in tumoral hypoxia mapping by PET imaging. Front Med (Lausanne). 2015;2:58. https://doi.org/10.3389/fmed.2015.00058.

28.

Bonekamp D, Deike K, Wiestler B, Wick W, Bendszus M, Radbruch A, et al. Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: comparison of intraindividually matched T₁- and T₂ ^*-based bolus techniques. J Magn Reson Imaging. 2015;42:87–96.CrossRefPubMed

29.

Coban G, Mohan S, Kural F, Wang S, O’Rourke DM, Poptani H. Prognostic value of dynamic susceptibility contrast-enhanced and diffusion-weighted MR imaging in patients with glioblastomas. AJNR Am J Neuroradiol. 2015;36:1247–52.CrossRefPubMed

30.

Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355:1253–61.CrossRefPubMed

31.

Yoshii Y, Furukawa T, Kiyono Y, Watanabe R, Waki A, Mori T, et al. Copper-64-diacetyl-bis (N ⁴-methylthiosemicarbazone) accumulates in rich regions of CD133⁺ highly tumorigenic cells in mouse colon carcinoma. Nucl Med Biol. 2010;37:395–404.CrossRefPubMed

32.

Ikawa M, Okazawa H, Tsujikawa T, Matsunaga A, Yamamura O, Mori T, et al. Increased oxidative stress is related to disease severity in the ALS motor cortex: A PET study. Neurology. 2015;84:2033–9.CrossRefPubMed

33.

Indo HP, Davidson M, Yen HC, Suenaga S, Tomita K, Nishii T, et al. Evidence of ROS generation by mitochondria in cells with impaired electron transport chain and mitochondrial DNA damage. Mitochondrion. 2007;7:106 – 18.CrossRefPubMed

34.

Okon IS, Zou MH. Mitochondrial ROS and cancer drug resistance: implications for therapy. Phamacol Res. 2015;100:170–4.CrossRef

Titel: Prognostic implications of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET/CT in patients with glioma
verfasst von: Akira Toriihara
Makoto Ohtake
Kensuke Tateishi
Ayako Hino-Shishikura
Tomohiro Yoneyama
Yoshio Kitazume
Tomio Inoue
Nobutaka Kawahara
Ukihide Tateishi
Publikationsdatum: 16.02.2018
Verlag: Springer Japan
Erschienen in: Annals of Nuclear Medicine
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-018-1241-4

Springer Medizin

Abstract

Objective

Method

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe

68Ga-DOTATATE PET–CT imaging in carotid body paragangliomas

The feasibility of 18F-FES and 18F-FDG microPET/CT for early monitoring the effect of fulvestrant on sensitizing docetaxel by downregulating ERα in ERα+ breast cancer

Biochemical and pathologic factors affecting technetium-99m-methoxyisobutylisonitrile imaging results in patients with primary hyperparathyroidism

Comparison of choline influx from dynamic 18F-Choline PET/CT and clinicopathological parameters in prostate cancer initial assessment

Improvement in the measurement error of the specific binding ratio in dopamine transporter SPECT imaging due to exclusion of the cerebrospinal fluid fraction using the threshold of voxel RI count

18F-FPYBF-2, a new F-18 labelled amyloid imaging PET tracer: biodistribution and radiation dosimetry assessment of first-in-man 18F-FPYBF-2 PET imaging